Portolan Capital Management, LLC Avadel Pharmaceuticals PLC Transaction History

Portolan Capital Management, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$8.48 - $16.48 $13,406 - $26,054	1,581 Added 0.55%	289,906 $4.78 Million
Q1 2023 May 15, 2023	BUY	$6.41 - $9.95 $1.85 Million - $2.87 Million	288,325 New	288,325 $2.64 Million
Q4 2018 Feb 13, 2019	SELL	$1.74 - $4.66 $262,044 - $701,796	-150,600 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$4.08 - $7.14 $21,913 - $38,348	-5,371 Reduced 3.44%	150,600 $661,000
Q2 2018 Aug 14, 2018	SELL	$5.89 - $7.78 $318,301 - $420,438	-54,041 Reduced 25.73%	155,971 $956,000
Q1 2018 May 14, 2018	BUY	$6.76 - $11.7 $1.42 Million - $2.46 Million	210,012 New	210,012 $1.53 Million

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $650M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Portolan Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Portolan Capital Management, LLC with notifications on news.